Tredje Ap Fonden Neurocrine Biosciences Inc Transaction History

Tredje Ap Fonden

$10.3 Billion
Q1 2025

A detailed history of Tredje Ap Fonden transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Tredje Ap Fonden holds 37,068 shares of NBIX stock, worth $4.55 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

37,068

Previous 9,364 295.86%

Holding current value

$4.55 Million

Previous $1.28 Million 220.74%

% of portfolio

0.04%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$107.22 - $153.29 $2.97 Million - $4.25 Million	27,704 Added 295.86%	37,068 $4.1 Million
Q4 2024 Feb 10, 2025	SELL	$111.62 - $139.44 $1.05 Million - $1.31 Million	-9,364 Reduced 50.0%	9,364 $1.28 Million
Q2 2024 Aug 12, 2024	SELL	$130.86 - $143.19 $37,818 - $41,381	-289 Reduced 1.52%	18,728 $2.58 Million
Q1 2024 May 13, 2024	BUY	$130.4 - $143.74 $463,832 - $511,283	3,557 Added 23.01%	19,017 $2.62 Million
Q4 2023 Feb 12, 2024	SELL	$106.07 - $132.76 $68,839 - $86,161	-649 Reduced 4.03%	15,460 $2.04 Million
Q3 2023 Nov 09, 2023	SELL	$94.02 - $117.1 $140,465 - $174,947	-1,494 Reduced 8.49%	16,109 $1.81 Million
Q2 2023 Aug 11, 2023	SELL	$89.53 - $104.87 $249,072 - $291,748	-2,782 Reduced 13.65%	17,603 $1.66 Million
Q1 2023 May 10, 2023	BUY	$94.11 - $123.02 $98,909 - $129,294	1,051 Added 5.44%	20,385 $2.06 Million
Q4 2022 Feb 10, 2023	SELL	$106.72 - $127.06 $12,272 - $14,611	-115 Reduced 0.59%	19,334 $2.31 Million
Q3 2022 Nov 10, 2022	BUY	$92.03 - $107.81 $1.79 Million - $2.1 Million	19,449 New	19,449 $2.07 Million

Others Institutions Holding NBIX

# of Institutions

650

Shares Held

97.2M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tredje Ap Fonden, based on Form 13F filings with the SEC.

News

Stay updated on Tredje Ap Fonden with notifications on news.

Account